{
    "root": "4d832ba0-8b5c-de5a-246a-a5f30e884bb4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Simvastatin",
    "value": "20230926",
    "ingredients": [
        {
            "name": "SIMVASTATIN",
            "code": "AGG2FN16EV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9150"
        },
        {
            "name": "ASCORBIC ACID",
            "code": "PQ6CK8PD0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_22652"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_76359"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "Anhydrous Citric Acid",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        }
    ],
    "indications": {
        "text": "simvastatin tablets indicated : reduce risk total mortality reducing risk coronary heart disease death , non-fatal myocardial infarction stroke , need coronary non-coronary revascularization procedures adults established coronary heart disease , cerebrovascular disease , peripheral vascular disease , and/or diabetes , high risk coronary heart disease events . adjunct diet reduce low-density lipoprotein cholesterol ( ldl-c ) : adults primary hyperlipidemia . adults pediatric patients aged 10 years older heterozygous familial hypercholesterolemia ( hefh ) . adjunct ldl-c-lowering therapies reduce ldl-c adults homozygous familial hypercholesterolemia ( hofh ) . adjunct diet treatment adults : primary dysbetalipoproteinemia . hypertriglyceridemia .",
        "doid_entities": [
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "peripheral vascular disease (DOID:341)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_341"
            },
            {
                "text": "vascular disease (DOID:178)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_178"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "familial hypercholesterolemia (DOID:13810)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13810"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "important information : ( 2.1 ) take simvastatin tablets orally daily evening . maximum recommended simvastatin tablets 40 mg daily . 80 mg daily simvastatin tablets restricted patients taking simvastatin 80 mg daily chronically ( e.g . , 12 months ) without evidence muscle toxicity . patients require high-intensity statin unable achieve ldl-c goal receiving simvastatin tablets 40 mg daily , prescribe alternative ldl-c lowering treatment . assess ldl-c clinically appropriate , early 4 weeks initiating , adjust necessary . adults : recommended 20 mg 40 mg daily . ( 2.2 ) pediatric patients aged 10 years older hefh : recommended 10 mg 40 mg daily . ( 2.3 ) patients severe renal impairment : recommended starting simvastatin 5 mg daily . ( 2.4 , 8.6 ) full prescribing information simvastatin tablets modifications due . ( 2.5 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "simvastatin tablets usp 5 mg white white , oval , biconvex , film-coated tablets logo \u201c b300 \u201d debossed one side \u201c 5 \u201d side . supplied follows : ndc 70377-001-12 bottles 30 ndc 70377-001-13 bottles 45 ndc 70377-001-14 bottles 90 ndc 70377-001-15 bottles 1000 simvastatin tablets usp 10 mg peach dark peach , oval , biconvex , film-coated tablets logo \u201c b301 \u201d debossed one side \u201c 10 \u201d side . supplied follows : ndc 70377-002-12 bottles 30 ndc 70377-002-13 bottles 45 ndc 70377-002-14 bottles 90 ndc 70377-002-15 bottles 1000 simvastatin tablets usp 20 mg orange dark orange , oval , biconvex , film-coated tablets logo \u201c b302 \u201d debossed one side \u201c 20 \u201d side . supplied follows : ndc 70377-003-12 bottles 30 ndc 70377-003-13 bottles 45 ndc 70377-003-14 bottles 90 ndc 70377-003-15 bottles 1000 simvastatin tablets usp 40 mg light pink pink , oval , biconvex , film-coated tablets logo \u201c b303 \u201d debossed one side \u201c 40 \u201d side . supplied follows : ndc 70377-004-12 bottles 30 ndc 70377-004-13 bottles 45 ndc 70377-004-14 bottles 90 ndc 70377-004-15 bottles 1000 simvastatin tablets usp 80 mg pink dark pink , capsule-shaped , film-coated tablets logo \u201c b304 \u201d debossed one side \u201c 80 \u201d side . supplied follows : ndc 70377-005-12 bottles 30 ndc 70377-005-13 bottles 45 ndc 70377-005-14 bottles 90 ndc 70377-005-15 bottles 1000 storage store 20 25\u00b0c ( 68 77\u00b0f ) . [ usp controlled room temperature ] . dispense tightly-closed container defined usp .",
    "adverseReactions": "simvastatin tablets contraindicated following conditions : concomitant strong cyp3a4 inhibitors ( select azole anti-fungals , macrolide antibiotics , anti-viral medications , nefazodone ) [ ( 7.1 ) ] . concomitant cyclosporine , danazol gemfibrozil [ ( 7.1 ) ] . acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . hypersensitivity simvastatin excipients simvastatin tablets . hypersensitivity , including anaphylaxis , angioedema stevens-johnson syndrome , reported [ ( 6.2 ) ] .",
    "indications_original": "Simvastatin tablets are indicated:\n                  \n                     \n                        To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events.\n                     \n                     \n                        As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C):\n                        \n                           \n                              In adults with primary hyperlipidemia.\n                           \n                           \n                              In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                           \n                        \n                     \n                  \n                  \n                     \n                        As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH).\n                     \n                  \n                  \n                     \n                        As an adjunct to diet for the treatment of adults with:\n                        \n                           \n                              Primary dysbetalipoproteinemia.\n                           \n                           \n                              Hypertriglyceridemia.",
    "contraindications_original": "Important Dosage and Administration Information: (2.1) Take simvastatin tablets orally once daily in the evening. Maximum recommended dosage is simvastatin tablets 40 mg once daily. An 80 mg daily dosage of Simvastatin tablets are restricted to patients who have been taking simvastatin\u00a0 80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity. For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving simvastatin tablets 40 mg daily, prescribe alternative LDL-C lowering treatment. Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating, and adjust the dosage if necessary. Adults : Recommended dosage is 20 mg to 40 mg once daily. (2.2) Pediatric Patients Aged 10 Years and Older with HeFH : Recommended dosage is 10 mg to 40 mg once daily. (2.3) Patients with Severe Renal Impairment : Recommended starting dosage is simvastatin 5 mg once daily. (2.4, 8.6) See full prescribing information for simvastatin tablets dosage modifications due to drug interactions. (2.5)",
    "warningsAndPrecautions_original": "Simvastatin Tablets USP 5 mg are white to off white, oval, biconvex, film-coated tablets with the logo \u201cB300\u201d debossed on one side and \u201c5\u201d on the other side. They are supplied as follows:\n                  \n                  \n                     NDC 70377-001-12 bottles of 30\n                  \n                     NDC 70377-001-13 bottles of 45\n                  \n                     NDC 70377-001-14 bottles of 90\n                  \n                     NDC 70377-001-15 bottles of 1000\n                  \n                  Simvastatin Tablets USP 10 mg are peach to dark peach, oval, biconvex, film-coated tablets with the logo \u201cB301\u201d debossed on one side and \u201c10\u201d on the other side. They are supplied as follows:\n                  \n                  \n                     NDC 70377-002-12 bottles of 30\n                  \n                     NDC 70377-002-13 bottles of 45\n                  \n                     NDC 70377-002-14 bottles of 90\n                  \n                     NDC 70377-002-15 bottles of 1000\n                  \n                  Simvastatin Tablets USP 20 mg are orange to dark orange, oval, biconvex, film-coated tablets with the logo \u201cB302\u201d debossed on one side and \u201c20\u201d on the other side. They are supplied as follows:\n                  \n                  \n                     NDC 70377-003-12 bottles of 30\n                  \n                     NDC 70377-003-13 bottles of 45\n                  \n                     NDC 70377-003-14 bottles of 90\n                  \n                     NDC 70377-003-15 bottles of 1000\n                  \n                  Simvastatin Tablets USP 40 mg are light pink to pink, oval, biconvex, film-coated tablets with the logo \u201cB303\u201d debossed on one side and \u201c40\u201d on the other side. They are supplied as follows:\n                  \n                  \n                     NDC 70377-004-12 bottles of 30\n                  \n                     NDC 70377-004-13 bottles of 45\n                  \n                     NDC 70377-004-14 bottles of 90\n                  \n                     NDC 70377-004-15 bottles of 1000\n                  \n                  Simvastatin Tablets USP 80 mg are pink to dark pink, capsule-shaped, film-coated tablets with the logo \u201cB304\u201d debossed on one side and \u201c80\u201d on the other side. They are supplied as follows:\n                  \n                  \n                     NDC 70377-005-12 bottles of 30\n                  \n                     NDC 70377-005-13 bottles of 45\n                  \n                     NDC 70377-005-14 bottles of 90\n                  \n                     NDC 70377-005-15 bottles of 1000\n                  \n                  \n                     Storage\n                  \n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n                  Store between 20 to 25\u00b0C (68 to 77\u00b0F). [See USP Controlled Room Temperature]. Dispense in a tightly-closed container as defined in the USP.",
    "adverseReactions_original": "Simvastatin tablets are contraindicated in the following conditions:\n                  \n                     \n                        Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1)].\n                        \n                     \n                     \n                        Concomitant use of cyclosporine, danazol or gemfibrozil [see Drug Interactions (7.1)].\n                        \n                     \n                     \n                        Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].\n                     \n                     \n                        Hypersensitivity to simvastatin or any excipients in simvastatin tablets. Hypersensitivity reactions, including anaphylaxis, angioedema and Stevens-Johnson syndrome, have been reported [see Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Simvastatin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9150"
        }
    ]
}